Harbour BioMed
Xiaoxiang Chen possesses extensive experience in the biopharmaceutical industry, currently serving as the Chief Development Officer at Harbour Biomed since November 2017, with responsibilities encompassing pre-clinical development, CMC, regulatory affairs, and clinical development for innovative drugs. Prior to this role, Xiaoxiang Chen held the position of Executive Vice President at Boehringer Ingelheim from January 2016 to November 2017, where expertise included regional medical leadership and oversight.
This person is not in any offices
Harbour BioMed
1 followers
Harbour BioMed is an Immune-Driven Global Bio-therapeutics Company discovering, developing and delivering Innovative Therapeutics for Oncology and Immunology. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery - the H2L2 and the HCAb.